Association between phthalate exposure and metabolic dysfunction-associated steatotic liver disease (MASLD) – systematic literature review

Environmental Research, Journal Year: 2025, Volume and Issue: unknown, P. 121186 - 121186

Published: Feb. 1, 2025

Language: Английский

---

Physicians' Perceptions and Practices on Metabolic Dysfunction-Associated Liver Disease: An Exploratory Survey

Ibnosina Journal of Medicine and Biomedical Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 28, 2025

Abstract Background There has been a rapid increase in the incidence and prevalence of metabolic dysfunction-associated liver disease (MASLD) Middle East Africa (MEA) regions. Methods We aimed to assess knowledge awareness MASLD among MEA physicians evaluate their current approach diagnosing, managing, referring MASLD. used an online survey through validated questionnaire convenience sample clinicians examine knowledge, practices, attitudes regarding barriers providing care for this condition. Results A total 128 completed survey. Most were from Arabian Gulf (72.6%). senior adult endocrinologists; 53.2% respondents considered general population around 10% or 30%; 28.6% felt that enzymes sufficiently sensitive detect underlying unsure whether Enhanced Liver Fibrosis score 4 could help identify those with high risk advanced fibrosis cirrhosis (54.5 29.1%, respectively, unsure). Although 83.8% would refer patient gastroenterologist if they suspect MASLD, 29.4% do not make referrals. Of concern, 64.5% participants unlikely hepatologist unless function tests are abnormal. Respondents identified several making Conclusion viewed as significant health concern. However, rates screening low. key obstacle managing these patients was lack Regional guidelines continuing professional development activities should focus on strategies at-risk patients, evidence-based management practices.

Language: Английский

---

Research progress on AMPK in the pathogenesis and treatment of MASLD

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 11, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD; formerly known as non-alcoholic fatty disease, NAFLD) has become one of the most prevalent chronic diseases worldwide, with its incidence continuously rising alongside epidemic metabolic disorders. AMP-activated protein kinase (AMPK), a key regulator cellular energy metabolism, influences multiple pathological processes associated MASLD. This review systematically summarizes regulatory roles AMPK in lipid inflammatory response, cell apoptosis, and fibrosis. Additionally, it discusses latest developments activators from preclinical to clinical studies, while analyzing major challenges currently faced potential strategies for resolution. A deeper understanding mechanisms will contribute development more effective therapeutic approaches

Language: Английский

---

Prediction of major liver-related events in the population using prognostic models

Gastroenterology report, Journal Year: 2025, Volume and Issue: 13

Published: Jan. 1, 2025

Abstract Liver disease poses a significant global health burden, with steatotic liver related to metabolic dysfunction and/or alcohol use being the most prevalent type. Current risk stratification strategies emphasize detecting advanced fibrosis as surrogate marker for liver-related events (LREs), such hospitalization, cancer, or death. However, alone does not adequately predict imminent outcomes, particularly in fast-progressing individuals without at evaluation. This underscores need models designed specifically LREs, enabling timely interventions. The Chronic Disease (CLivD) score, dynamic aspartate aminotransferase-to-alanine aminotransferase ratio (dAAR), and Cirrhosis Outcome Risk Estimator (CORE) were explicitly developed LRE rather than detect fibrosis. Derived from general population cohorts, these incorporate either standard enzymes (dAAR CORE) factors (CLivD), broad application primary care population-based settings. They directly estimate of future improving on traditional fibrosis-focused approaches. Conversely, widely used like Fibrosis-4 index newer ones, LiverRisk LiverPRO scores, initially significant/advanced stiffness. While prediction, they have later been analyzed this purpose. Integrating screening LRE-focused CLivD, dAAR, CORE can help healthcare systems adopt proactive, preventive care. approach emphasizes identifying severe potentially ensuring better resource allocation personalized

Language: Английский

---

Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?

Archives of Medical Science - Atherosclerotic Diseases, Journal Year: 2025, Volume and Issue: 10(1), P. 1 - 15

Published: March 14, 2025

More than 25% of the adult population worldwide and approximately 50–75% patients with type 2 diabetes are diagnosed non-alcoholic fatty liver disease. Insulin resistance is one most crucial factors underlying its pathogenesis a significant determinant progression to steatohepatitis. The complex pathophysiology disease emphasizes need for combination treatment strategies drug classes that target different cellular pathways, since no single agent can control all mechanisms contributing development evolution. Pioglitazone, main thiazolidinedione in clinical practice, only true insulin sensitizing antidiabetic our therapeutic armamentarium diabetes. Current international practice guidelines recommend PIO as promising therapy who experience NASH GLP-1 receptor agonists SGLT2 inhibitors have shown salutary cardiometabolic renal effects diabetes, well beneficial activities those This review discusses pathophysiological background use these three categories It also explores thoroughly combinations pioglitazone either or inhibitors, their future role this setting.

Language: Английский

---

Vascular endothelial growth factor A, a potential non-invasive biomarker for metabolic dysfunction-associated steatotic liver disease progression

Clinical Biochemistry, Journal Year: 2025, Volume and Issue: unknown, P. 110920 - 110920

Published: March 1, 2025

Liver fibrosis is the primary predictor of complications in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, there are currently no non-invasive prognostic tests to stratify at risk for hepatic progression. This study aimed explore whether plasma proteins could serve as biomarkers monitoring MASLD Blood protein analysis was performed on samples from a long-term follow-up repeated biopsies. Over 1100 covering broad range biological processes were analyzed using 13 Olink® Target 96 panels. Protein level changes compared between different time points and or without an increase stage two Increased vascular endothelial growth factor A (VEGFA) levels significantly associated progression histologically assessed stage. These findings suggest that VEGFA may be effective biomarker MASLD.

Language: Английский

---

Electroacupuncture Attenuates Intestinal Barrier Disruption via the α7nAChR-Mediated HO-1/p38 MAPK/NF-κB Pathway in a Mouse Model of Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized, Single-Blind, Controlled Trial

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 802 - 802

Published: March 27, 2025

Background: Gut barrier integrity plays a crucial role in the pathogenesis of metabolic dysfunction-associated fatty liver disease (MAFLD). Electroacupuncture (EA) at ST-36 can ameliorate inflammatory responses via stimulating α7 nicotinic acetylcholine receptor (α7nAChR), but whether EA is effective preserving intestinal MAFLD has not been exactly illustrated. This investigation explored potential protection mechanisms targeting dismantled gut MAFLD. Methods: C57BL/6 mice were randomly allocated into several subgroups: control (CON), high-fat diet (HFD), HFD with EA, and α7nAChR inhibitor α-BGT, HO-1 knockout (KO). Body weight, visceral fat index, histopathological examination intestine determined. Serum biological indexes evaluated through corresponding kits. Furthermore, expressions HO-1, α7nAChR, barrier-associated proteins, molecular tissues assessed Western blot, RT-qPCR, immunohistology, or immunofluorescence examination. Results: treatment decreased body index gain mitigated function injury abnormal lipid indexes, exhibiting less severity hepatic steatosis, fibrosis, inflammation Lower permeability, epithelial disruption, upregulation tight junction proteins after suggested protective effects attenuating dysfunction. These abolished by α-BGT deletion. Mechanistically, markedly enriched expression phosphorylated p38 MAPK/NF-κB activation, which was lost KO treatment. Conclusions: The may be attributed to preserved barrier, thereby alleviating systemic preventing subsequent hits, where α7nAChR-mediated HO-1/p38 pathway maintain homeostasis.

Language: Английский

---

A negative correlation of low estimated glucose disposal rate with significant liver fibrosis in adults with NAFLD and obesity: results from NHANES 2017–2020

BMC Gastroenterology, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 29, 2025

Abstract Background and aim Nonalcoholic fatty liver disease (NAFLD) with fibrosis is associated liver-related mortality cardiovascular disease. Estimated glucose disposal rate (eGDR), which an insulin resistance–related index, related to the caused by NAFLD. This study aimed investigate predictive value of eGDR for in patients Methods The data from National Health Nutrition Examination Survey 2017–2020.03 were analyzed present study. NAFLD was diagnosed using controlled attenuation parameter (CAP) tests FibroScan ® model 502 V2 Touch. Results 1585 individuals analyzed, including 224 significant 1361 nonsignificant fibrosis. Individuals older had higher CAP values lower eGDRs (both P < 0.01). A negative correlation found between stiffness degrees (odds ratio: 0.643, 95% confidence interval: 0.643–0.726, 0.001); also after adjusting age, sex, ethics ( 0.001). For participants obesity overweight, negatively correlated CAP, body mass index (BMI), waist circumference, C-reactive protein level, white blood cell (WBC) count (all 0.05). multivariate analysis revealed that eGDR, BMI, aspartate aminotransferase (AST), WBC platelet (PLT) counts 0.05) independent risk factors incorporating AST, WBC, PLT AUROC 0.822, superior conventional noninvasive scoring systems, AST-to-PLT ratio fibrosis-4 gamma-glutamyl transpeptidase Conclusion Low obesity, a demonstrated strong evaluation.

Language: Английский

---

Metabolic dysfunction-associated steatotic liver disease and malignancies: Unmasking a silent saboteur

Metabolism, Journal Year: 2025, Volume and Issue: unknown, P. 156253 - 156253

Published: March 1, 2025

Language: Английский

---

Spatial Viscoelastic Information in Metabolic Dysfunction–associated Steatotic Liver Disease

Radiology, Journal Year: 2025, Volume and Issue: 315(1)

Published: April 1, 2025

Language: Английский

---